SPP1 improves risk assessment for pregnant people with PAH

Robyn Kalda
11 hours ago
1 min read

Secreted phosphoprotein 1 (SPP1) levels were higher in patients with PAH, and SPP1 levels were associated with disease severity. Patients who had postpartum adverse events had higher SPP1 concentrations.

SPP1 may act as a predictor of adverse postpartum events for people with pulmonary arterial hypertension (PAH), along with other clinical indicators.

Read the European Journal of Obstetrics and Gynecology and Reproductive Biology article

Recent Posts

In PAH, palliative care discussions need to be proactive

A survey of 200 people in the United States living with pulmonary arterial hypertension (PAH) found that 85% had never discussed palliative care with their healthcare provider, even though nearly nine

Endoplasmic reticulum stress induces a pathway that accelerates PAH progression

This study found that endoplasmic reticulum stress in lung blood vessels may contribute to pulmonary arterial hypertension (PAH) by triggering pyroptosis and damaging blood vessels. In rats, blocking

Phase 3 ADVANCE OUTCOMES trial on ralinepag succeeds

Patients with pulmonary arterial hypertension who took ralinepag in addition to their usual treatment were less likely to have their disease get worse than those who took a placebo. However, more peop

Comments